Eurofins

The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.

The system combines sample preparation technology capable of amplifying tens of thousands of locations in the genome with next-generation sequencing.

Genoma, which is based in Italy, offers a wide range of specialty diagnostics services with an emphasis on noninvasive prenatal testing, as well as oncology tests. 

An OpenArray panel designed to simultaneously test for 17 viruses and 13 bacteria and protozoa was able to detect pathogens from human blood donor samples with an accuracy of about 95 percent.

The deal will close in July and will expand Eurofins' capabilities in areas including DNA sequencing and genetic testing. 

The deal is expected to expand Eurofin's clinical diagnostic footprint in Europe.

The lab was opened earlier this year as the company's central genomics lab in North America, offering various genomic services such as DNA sequencing.

The company is hoping to find a niche among customers who want the quality of high-throughput oligonucleotide synthesis but smaller order volumes.

Living DNA can break down the origins of a customer’s ancestry into 21 distinct regions within Britain alone, as well as across 80 different worldwide populations.

Pages

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.